Table 4 Major renal events during follow-up according to BMI categories at baseline, in each randomised group

From: Associations between body mass index and the risk of renal events in patients with type 2 diabetes

  

Major renal events

HR (95% CI)

  

No

Yes

 

Glucose lowering control (p for interaction = 0.14)

 Standard

Normal weight

1374

84

Ref.

Overweight

2086

100

0.91 (0.67–1.23)

Obesity grade 1

1063

58

1.08 (0.74–1.57)

Obesity grade 2

355

16

1.06 (0.60–1.88)

Obesity grade 3

128

11

2.00 (1.02–3.92)

 Intensive

Normal weight

1376

60

Ref.

Overweight

2073

81

0.90 (0.63–1.28)

Obesity grade 1

1106

38

0.94 (0.60–1.48)

Obesity grade 2

346

27

1.72 (1.02–2.91)

Obesity grade 3

143

12

2.23 (1.13–4.43)

Blood pressure treatment (p for interaction = 0.88)

 Placebo

Normal weight

1374

80

Ref.

Overweight

2072

97

0.86 (0.63–1.17)

Obesity grade 1

1071

41

0.82 (0.54–1.24)

Obesity grade 2

369

22

1.36 (0.80–2.30)

Obesity grade 3

138

15

2.54 (1.37–4.68)

 Perindopril-indapamide

Normal weight

1376

64

Ref.

Overweight

2087

84

0.95 (0.68–1.34)

Obesity grade 1

1098

55

1.25 (0.84–1.87)

Obesity grade 2

332

21

1.43 (0.83–2.47)

Obesity grade 3

133

8

1.61 (0.74–3.52)

  1. Hazard ratios computed by Cox proportional hazards regression analyses adjusted as in model 1: baseline age, sex, region of origin, prior cardiovascular disease, estimated glomerular filtration rate (and its square), urinary albumin to creatinine ratio, history of ever smoking, glucose control (analyses in blood pressure treatment groups) and blood pressure (analyses in glucose control groups) study allocations. The p-values represent tests for interaction between study treatment groups
Back to article page